LONDON (ShareCast) - (Sharecast News) - Advanced Medical Solutions (AMS) on Friday said that its growth has been hindered by a drop in sales of its US LiquiBand range, though overall trading remains in line with full-year expectations.
A reduction in sales of US LiquiBand was predominantly the result of destocking as some customers have not replenished high inventories built for Brexit, while like-for-like sales for the comparative first half period were enhanced for AMS by competitor supplier issues.

The AIM traded surgical and advanced woundcare specialist said it remains confident that US LiquiBand will return to strong growth in 2020 given the expected launch of its new Liquiband XL device in the first half of the year.

In the meantime, AMS claimed that the "temporary shortfall" from US Liquiband has been offset by other parts of the group showing strong growth.

Chris Meredith, chief executive of AMS, said: "I am pleased to report that overall the group continues to perform well and we are trading in line with the board's expectations for the full year. Looking ahead, we are excited about the growth prospects for the business, the integration of Sealantis and the expected impact from new product launches. AMS is in a robust position and we are confident on delivering our stated growth strategy."

Advanced Medical Solutions' shares were down 5.16% at 303.50p at 0942 BST.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE